Hair Loss Profiles and Ritlecitinib Efficacy in Patients with Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study
Abstract Introduction Ritlecitinib demonstrated efficacy in patients with alopecia areata (AA) in the ALLEGRO phase 2b/3 study (NCT03732807). However, hair loss presentation may vary based on location (e.g., scalp, eyebrow/eyelash, body). Here, we sought to identify distinct hair loss profiles at ba...
Saved in:
Main Authors: | Diamant Thaçi (Author), Christos Tziotzios (Author), Taisuke Ito (Author), Justin Ko (Author), Ayşe Serap Karadağ (Author), Hong Fang (Author), Roger A. Edwards (Author), Gianluca Bonfanti (Author), Robert Wolk (Author), Helen Tran (Author), Ernest Law (Author) |
---|---|
Format: | Book |
Published: |
Adis, Springer Healthcare,
2023-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Impact of Previous Alopecia Areata Treatment on Efficacy Responses up to Week 48 Following Ritlecitinib Treatment: A Post Hoc Analysis
by: Jennifer Fu, et al.
Published: (2024) -
Safety and Efficacy of Ritlecitinib and Brepocitinib in Alopecia Areata: Results from the Crossover Open-Label Extension of the ALLEGRO Phase 2a Trial
by: Brett King, et al.
Published: (2022) -
Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata
by: Ramírez-Marín HA, et al.
Published: (2022) -
Which is the ideal JAK inhibitor for alopecia areata - Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
by: Kabir Sardana, et al.
Published: (2023) -
A phase 2a study investigating the effects of ritlecitinib on brainstem auditory evoked potentials and intraepidermal nerve fiber histology in adults with alopecia areata
by: Samira Anderson, et al.
Published: (2024)